Cargando…
Comparison of Abbott ID Now, DiaSorin Simplexa, and CDC FDA Emergency Use Authorization Methods for the Detection of SARS-CoV-2 from Nasopharyngeal and Nasal Swabs from Individuals Diagnosed with COVID-19
Autores principales: | Rhoads, Daniel D., Cherian, Sree S., Roman, Katharine, Stempak, Lisa M., Schmotzer, Christine L., Sadri, Navid |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383529/ https://www.ncbi.nlm.nih.gov/pubmed/32303564 http://dx.doi.org/10.1128/JCM.00760-20 |
Ejemplares similares
-
Molecular Detection of Candida auris Using DiaSorin Molecular Simplexa(®) Detection Kit: A Diagnostic Performance Evaluation
por: Ramírez, Juan David, et al.
Publicado: (2023) -
New Faecal Calprotectin Assay by IDS: Validation and Comparison to DiaSorin Method
por: Castiglione, Vincent, et al.
Publicado: (2022) -
Detection of SARS-CoV-2 infection in asymptomatic populations using the DiaSorin molecular Simplexa and Roche Cobas EUA assays
por: Antonara, Stella, et al.
Publicado: (2022) -
Clinical Utilization of DiaSorin Molecular Polymerase Chain Reaction in Pneumocystis Pneumonia
por: Damhorst, Gregory L, et al.
Publicado: (2022) -
Clinical Assessment of the DiaSorin LIAISON SARS-CoV-2 Ag Chemiluminescence Immunoassay
por: Salvagno, Gian Luca, et al.
Publicado: (2021)